.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
AstraZeneca
Cantor Fitzgerald
McKesson
US Department of Justice
Citi
Chubb
Fuji
Deloitte
Moodys

Generated: June 25, 2017

DrugPatentWatch Database Preview

CAPOTEN Drug Profile

« Back to Dashboard

What is the patent landscape for Capoten, and what generic Capoten alternatives are available?

Capoten is a drug marketed by Par Pharm and is included in one NDA.

The generic ingredient in CAPOTEN is captopril. There are fourteen drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the captopril profile page.

Summary for Tradename: CAPOTEN

Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: see list58
Clinical Trials: see list1
Patent Applications: see list8,303
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:CAPOTEN at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-005Jan 17, 1985DISCNYesNo► Subscribe► Subscribe
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-004Jun 13, 1995DISCNYesNo► Subscribe► Subscribe
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-002Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-006Sep 17, 1986DISCNYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: CAPOTEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-002Approved Prior to Jan 1, 19825,238,924► Subscribe
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-004Jun 13, 19954,215,104► Subscribe
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-001Approved Prior to Jan 1, 19824,105,776► Subscribe
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-001Approved Prior to Jan 1, 19825,238,924► Subscribe
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-005Jan 17, 19854,105,776► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Federal Trade Commission
AstraZeneca
Dow
Boehringer Ingelheim
Mallinckrodt
Baxter
Covington
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot